Legal Notice
All content of this Internet site is owned or controlled by Ortho-Mcneil Neurologics and is protected
by worldwide copyright laws. You may download content only for your personal use for non-commercial
purposes but no modification or further reproduction of the content is permitted. The content may
otherwise not be copied or used in any way.
The owners of this site will use reasonable efforts to include up-to-date and accurate information
in this Internet site, but makes no representations, warranties, or assurances as to the accuracy,
currency, or completeness of the information provided. The owners of this site shall not be liable
for any damages or injury resulting from your access to, or inability to access, this Internet site,
or from your reliance on any information provided at this Internet site. This site is for residents
of the United States and Puerto Rico.
This Internet site may provide links or references to other sites but the owners of this site have
no responsibility for the content of such other sites and shall not be liable for any damages or injury
arising from that content. Any links to other sites are provided as merely a convenience to the users
of this Internet site.
The trademarks, service marks, trade names, trade dress and products in this Internet site are protected
in the United States and internationally. No use of any of these may be made without the prior written
authorization of the owners of this site, except to identify the products or services of the company.
Any personally identifiable information in electronic communications to this Internet site is governed
by this site’s Privacy Policy. The owners of this site shall be free
to use or copy all other information in any such communications, including any ideas, inventions,
concepts, techniques or know-how disclosed therein, for any purposes. Such purposes may include disclosure
to third parties and/or developing, manufacturing and/or marketing goods or services.
The sender of any communications to this Internet site or otherwise to the owners of this site shall
be responsible for the content and information contained therein, including its truthfulness and accuracy.
About TOPAMAX
TOPAMAX is approved as initial monotherapy in patients 10 years of age and older with partial-onset
or primary generalized tonic-clonic seizures.
Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more
than 2 seizures in the 3 months prior to enrollment. Safety and effectiveness in patients
who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not
been established in controlled trials.
TOPAMAX is approved as add-on therapy for patients 2 years of age and older with primary generalized
tonic-clonic seizures, partial-onset seizures, or seizures associated with Lennox-Gastaut syndrome.
Important Safety Information
Serious risks associated with TOPAMAX include lowered bicarbonate levels in the blood resulting in an
increase in the acidity of the blood (metabolic acidosis). Symptoms could include hyperventilation
(rapid, deep breathing), tiredness, loss of appetite, irregular heartbeat or changes in the level of alertness.
Call your doctor immediately if you get these symptoms. Your doctor may want to do simple blood tests. Chronic,
untreated metabolic acidosis may increase the risk for kidney stones or bone disease.
Other serious risks include decreased sweating, increased body temperature, kidney stones, sleepiness,
dizziness, confusion, difficulty concentrating, and increased eye pressure (glaucoma). Call your doctor
immediately if you have any decrease in vision or eye pain. These problems can lead to blindness if not
treated right away.
More common side effects in adults are nervousness, coordination problems, fatigue, speech problems, slowed
thinking, memory difficulty, tingling in arms and legs, and double vision; and in children, fatigue, loss of appetite,
nervousness, memory difficulty, aggressive behavior, and weight loss.
As monotherapy, the most common side effects of TOPAMAX (in the 400 mg/day group and at a rate higher than the 50
mg/day group) in adults were tingling in arms and legs, weight decrease, sleepiness, loss of appetite, dizziness, and
difficulty with memory; and in children, weight decrease, upper respiratory tract infection, tingling in arms and legs,
loss of appetite, diarrhea, and mood problems.
In combination with other antiepileptic drugs (AEDs), the most common side effects of TOPAMAX in adults (200 to 400 mg/day)
were sleepiness, dizziness, nervousness, loss of muscle coordination, fatigue, speech disorders and related problems, psychomotor
slowing, abnormal vision, difficulty with memory, tingling in arms and legs, and double vision; and in children (5 to 9 mg/kg/day), fatigue,
sleepiness, loss of appetite, nervousness, difficulty with concentration/attention, difficulty with memory, aggressive reaction, and weight decrease.
Tell your doctor about other medications you take.
Please see full U.S. Prescribing Information.
© Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1999-2008. All rights reserved.
Your use of the information on this site is subject to the terms of our Legal Statement. Please see our Privacy Policy.
This site is published by Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., which is solely responsible for its contents.
Capitalized product names are trademarks of Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
This information is intended for use by our customers, patients and healthcare professionals in the United States only. Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside the United States.
This site was last modified on: Jul 26 2007 at 13:45:29 EDT